ABBVIE
- Country
- πΊπΈUnited States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function
- First Posted Date
- 2023-07-11
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 58
- Registration Number
- NCT05940402
- Locations
- πΊπΈ
Tustin, California, Tustin, California, United States
πΊπΈMiami, Florida, Miami, Florida, United States
πΊπΈOrlando, Florida, Orlando, Florida, United States
A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 38
- Registration Number
- NCT05935033
- Locations
- πΊπΈ
Miami, Florida, Miami, Florida, United States
πΊπΈOrlando, Florida, Orlando, Florida, United States
πΊπΈSan Antonio, Texas, San Antonio, Texas, United States
Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.
- Conditions
- Crohn's Disease
- First Posted Date
- 2023-07-05
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1200
- Registration Number
- NCT05930275
- Locations
- π§π¬
MC Nadejda Femily EOOD /ID# 267585, Varna, Bulgaria
π§π¬DCC Mladost M /ID# 267586, Varna, Bulgaria
π«π·CHU Amiens-Picardie Site Sud /ID# 259121, Amiens CEDEX 1, Somme, France
An Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's Disease
- Conditions
- Parkinson's Disease (PD)
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 250
- Registration Number
- NCT05916157
- Locations
- π―π΅
Municipal Toyonaka Hospital /ID# 271277, Toyonaka, Japan
π―π΅Saiseikai Matsuyama Hospital /ID# 276259, Matsuyama, Ehime, Japan
π―π΅University Hospital Kyoto Prefectural University of Medicine /ID# 267445, Kyoto-shi, Kyoto, Japan
Study to Assess Adverse Events and Compare How Crushed, Ground, and Intact Oral Tablets Venetoclax Moves Through the Body of Healthy Female Adult Volunteers
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 15
- Registration Number
- NCT05909553
- Locations
- πΊπΈ
Acpru /Id# 255783, Grayslake, Illinois, United States
A Study to Assess Drug-Drug Interaction Between ABBV-903 and Midazolam in Adult Healthy Volunteers
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 24
- Registration Number
- NCT05895266
- Locations
- πΊπΈ
Acpru /Id# 254970, Grayslake, Illinois, United States
Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteers
- First Posted Date
- 2023-06-07
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 24
- Registration Number
- NCT05892757
- Locations
- πΊπΈ
Bio-Kinetic Clinical Applications, LLC /ID# 255452, Springfield, Missouri, United States
πΊπΈIcon /Id# 257525, Salt Lake City, Utah, United States
πΊπΈIcon /Id# 257524, San Antonio, Texas, United States
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1328
- Registration Number
- NCT05889182
- Locations
- π¨π¦
Dermatology Research Institute - Blackfoot Trail /ID# 261413, Calgary, Alberta, Canada
π³π±Universitair Medisch Centrum Groningen /ID# 253571, Groningen, Netherlands
πͺπΈHospital Universitario Ramon y Cajal /ID# 253871, Madrid, Spain
A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult Participants
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 40
- Registration Number
- NCT05878067
- Locations
- πΊπΈ
Canyon City Eyecare /ID# 253652, Azusa, California, United States
Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine
- First Posted Date
- 2023-05-16
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 523
- Registration Number
- NCT05861427
- Locations
- π―π΅
Konan Medical Center /ID# 245557, Kobe-shi, Hyogo, Japan
π―π΅Nishinomiya Municipal Central Hospital /ID# 246571, Nishinomiya-shi, Hyogo, Japan
π―π΅Yamaguchi Clinic /ID# 246370, Nishinomiya-shi, Hyogo, Japan